Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

NCT02635984 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Complications of Bone Marrow Transplant
Hematologic Neoplasms

Interventions

DRUG: Olanzapine
DRUG: Placebo

Sponsor

Augusta University

Collaborators

[object Object]